Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425

Cancer Biology and Therapy

Volumn 7, Issue 5, 2008, Pages 726-733

  Kamat, Vishal ^a   Donaldson, Joshua M ^b   Kari, Csaba ^b   Quadros, Marlene R D ^b   Lelkes, Peter I ^a   Chaiken, Irwin ^c   Cocklin, Simon ^c   Williams, John C ^b   Papazoglou, Elisabeth ^a   Rodeck, Ulrich ^b,d  

^a DREXEL UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

Antagonist antibodies; C225; EGFR; Epitope mapping; Synergy

Indexed keywords

425 MONOCLONAL ANTIBODY; CETUXIMAB; EMD 559900; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPITOPE; MONOCLONAL ANTIBODY; MUTANT PROTEIN; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR ALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR; MATUZUMAB; TYRPHOSTIN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; DRUG ACTIVITY; DRUG BINDING SITE; DRUG EFFECT; DRUG INHIBITION; DRUG ISOLATION; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; NEOPLASM; PROTEIN PHOSPHORYLATION; SURFACE PLASMON RESONANCE; TUMOR GROWTH; ULTRACENTRIFUGATION; WILD TYPE; ANIMAL; CELL STRAIN 3T3; CHEMISTRY; CONFORMATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG SCREENING; EPITOPE MAPPING; MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; EPITOPE MAPPING; EPITOPES; HUMANS; MICE; MOLECULAR CONFORMATION; NIH 3T3 CELLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TYRPHOSTINS;

EID: 45349098002     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.5.6097     Document Type: Article

References (22)

1. Yarden Y, Sliwkowski MX. Untangling the ERBB signalling network. Nature Reviews Molecular Cell Biology 2001; 2:127-37.
2. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19:6550-65.
3. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001; 13:506-13.
4. Nagane M, Lin H, Cavenee WK, Huang HJ. Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett 2001; 162:17-21.
5. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23:2445-59.
6. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984; 44:1002-7.
7. Murthy U, Basu A, Rodeck U, Herlyn M, Ross AH, Das M. Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys 1987; 252:549-60.
8. Rodeck U, Herlyn M, Herlyn D, Molthoff C, Atkinson B, Varello M, Steplewski Z, Koprowski H. Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects. Cancer Res 1987; 47:3692-6.
9. Moscatello DK, Montgomery RB, Sundareshan P, McDanel H, Wong MY, Wong AJ. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 1996; 13:85-96.
10. Ferguson KM. Active and inactive conformations of the epidermal growth factor receptor. Biochem Soc Trans 2004; 32:742-5.
11. Jost M, Huggett TM, Kari C, Rodeck U. Matrix-independent Survival of Human Keratinocytes through an EGF Receptor/MAPK-Kinase-dependent Pathway. Molecular Biology of the Cell 2001; 12:1519-27.
12. Thali M, Moore JP, Furman C, Charles M, Ho DD, Robinson J, Sodroski J. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993; 67:3978-88.
13. Arkin M, Lear JD. A new data analysis method to determine binding constants of small molecules to proteins using equilibrium analytical ultracentrifugation with absorption optics. Anal Biochem 2001; 299:98-107.
14. Nahta R, Hung MC, Esteva FJ. The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells. Cancer Res 2004; 64:2343-6.
15. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, McLeod C, Mendelsohn J. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. Journal of Biological Chemistry 1984; 259:7755-60.
16. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301-11.
17. Biscardi JS, Belsches AP, Parsons SJ. Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. Mol Carcinog 1998; 21:261-72.
18. L expression through a MEK-dependent pathway. Journal of Biological Chemistry 2001; 276:6320-6.
19. Lax I, Fischer R, Ng C, Segre J, Ullrich A, Givol D, Schlessinger J. Noncontiguous regions in the extracellular domain of EGF receptor define ligand-binding specificity. Cell Regul 1991; 2:337-45.
20. Wen X, Wu QP, Ke S, Ellis L, Charnsangavej C, Delpassand AS, Wallace S, Li C. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225. J Nucl Med 2001; 42:1530-7.
21. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110:775-87.
22. DeLano WL. Unraveling hot spots in binding interfaces: progress and challenges. Curr Opin Struct Biol 2002; 12:14-20.